Evolving treatment paradigms in
lung cancer – role of Immuno-Oncology
Date: Friday 17th October
Time: 7:30 – 8:30am
Location: Plaza P9 to P11
Chaired by:
A/Prof. Paul Mitchell
Program
7:00–7:30am Breakfast available
7:30–7:50amStimulating immune response to fight cancer
–b
asic biology and mechanisms of action of
cancer immunotherapies
Prof. Ken O’Byrne (Princess Alexandra Hospital, QLD)
7:50–8:10amWhat’s the data demonstrating?
– clinical experience & clinical trials in lung cancer
Dr Thomas John (Austin Hospital, VIC)
8:10–8:30amPanel discussion – answering your questions
about Immuno-Oncology
Chaired by A/Prof. Paul Mitchell
(Austin Hospital, VIC)
BMS sponsored symposium at ALCC 2014, developed by independent steering committee members. In line with the Medicines Australia
Code of Conduct, hospitality can only be extended to invited healthcare professionals attending the above meeting as delegates. Guests
or family members cannot be accommodated. There will be no organization, subsidy or provision of travel, accommodation or hospitality
for them. The cost of all hospitality provided for this meeting will be disclosed in a report that is published online. The names of attendees
will not be included. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as requested by their employer
or professional association.BMS respects your privacy, and complies with the Amended Privacy Act 1988 (Cth) and the Australian Privacy
Principles. For further details on how BMS collects, stores, uses and discloses your personal information please see our privacy statement
at www.bmsa.com.au. If you wish to enquire about, rectify, update any personal information that BMS holds about you, cease receiving
information from us, request a copy of the BMS privacy statement or complain about the processing of your personal information,
then please write to us c/o The Privacy Officer, Bristol-Myers Squibb Australia Pty Ltd, Level 2, 4 Nexus Court, Mulgrave, VIC, 3170.
Bristol-Myers Squibb is investigating the potential
role of Immuno-Oncology in lung cancer
Immuno-Oncology (I-O) is a rapidly emerging therapeutic modality that has
the potential to change how metastatic lung cancer is treated.1 By finding new
ways to stop lung cancer from evading the immune system, I-O therapy may
be able to help restore the body’s natural ability to fight it. 2,3
References: 1. Devita VT Jr, Rosenberg SA. N Eng J Med 2012;366:2207–2214. 2. Borghaei H et al. Eur J
Pharmacol 2009;625(1–3):41–54. 3. Finn OJ. Ann Oncol 2012;23 Suppl 8(viii6–9). BMS Medical Information:
1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, 4 Nexus Court, Mulgrave,
VIC 3170. Ph +61 3 8523 4200. ONC/0026/09–14. Date of preparation: September 2014. BYV0214 09/14.